King Pharmaceuticals KG General Liability — Incurred loss and LAE, net of reinsurance

Other product segments

Similar metrics at other companies

CNAGeneral Liability — Incurred claims and allocated claim adjustment expense, net

915,100,000,000%+788,000,000,000pp

WTMProperty and Accident & Health — Incurred Loss and LAE, Net of Reinsurance

$1.52B+316%

FRHCCivil Liability — Incurred losses and LAE, net of reinsurance for the years ended March 31

$11.68M+45.2%

ACICNet Losses And LAE Incurred

$11.51M-33.6%

WRBProfessional liability — Loss and loss expenses incurred, net of reinsurance

$4.79B+634%

WTMSpecialty — Incurred Loss and LAE, Net of Reinsurance

$918.1M+311%

Questions, answered.

What is King Pharmaceuticals's general liability — incurred loss and LAE, net of reinsurance?

King Pharmaceuticals (KG) reported general liability — incurred loss and LAE, net of reinsurance of 111,127,700,000% in Q4 2025.

How has King Pharmaceuticals's general liability — incurred loss and LAE, net of reinsurance changed year-over-year?

King Pharmaceuticals's general liability — incurred loss and LAE, net of reinsurance increased by 539.2% year-over-year, from 17,385,300,000% to 111,127,700,000%.

What does general liability — incurred loss and LAE, net of reinsurance mean?

This metric represents the total cost of claims and associated loss adjustment expenses for the general liability segment, adjusted for reinsurance recoveries. It reflects the net underwriting impact of claims occurring within a specific period, serving as a primary indicator of underwriting profitability and risk exposure.